27485707|t|The role of IGF-1 and the distribution of body fat in decreasing the number of prostate rebiopsies
27485707|a|To assess the usefulness of IGF-1 and internal organ fat measured by bioelectrical impedance audiometry to avoid rebiopsies in patients with persistently high prostate-specific antigen (PSA) levels. A prospective study was conducted with 92 patients who underwent prostate rebiopsy due to high PSA levels with negative results in the rectal examination and a lack of preneoplastic lesions. The patients previously had their IGF-1 levels measured and had undergone an impedance audiometry test using the abdominal Fat Analyser AB-140 TANITA system. We calculated the receiver operating characteristic (ROC) curves for the PSA levels, % PSA, internal organ fat and IGF-1 and PSA density. Twenty-five patients were diagnosed with prostate cancer. These patients had significantly higher PSA, PSAd and IGF-1 values and a tendency towards higher internal organ fat levels and lower % PSA readings (p=.001, p=.003, p=.001, p=.24 and P=0.28, respectively). The ROC curve showed an area under the curve for IGF-1 and PSA of .82 and .81, respectively. Using the cutoff points for 95% sensitivity and using the 3 criteria as an indication of rebiopsy, 74% of the biopsies would have been spared, leaving undiagnosed only 1 patient with clinically significant cancer - Gleason score >7 (4+3)-. The positive and negative predictive values for the set of variables were higher than for each one separately (PPV: 66/NPV: 63). The cost of both determinations was 82 euros. Our results suggest that measuring IGF-1 could significantly decrease the number of unnecessary rebiopsies in an inexpensive and safe manner.
27485707	4	8	role	T077	C1705810
27485707	12	17	IGF-1	T116,T123	C0021665
27485707	26	38	distribution	T169	C1704711
27485707	42	50	body fat	T201	C0344335
27485707	54	64	decreasing	T033	C0442797
27485707	69	75	number	T081	C0449788
27485707	79	98	prostate rebiopsies	T060	C0194804
27485707	102	108	assess	T052	C1516048
27485707	113	123	usefulness	T080	C3827682
27485707	127	132	IGF-1	T116,T123	C0021665
27485707	137	155	internal organ fat	T201	C0344335
27485707	156	164	measured	T080	C0444706
27485707	168	191	bioelectrical impedance	T039	C0162536
27485707	192	202	audiometry	T060	C0004286
27485707	212	222	rebiopsies	T060	C0005558
27485707	226	234	patients	T101	C0030705
27485707	240	252	persistently	T078	C0750508
27485707	253	296	high prostate-specific antigen (PSA) levels	T033	C4293696
27485707	300	317	prospective study	T062	C0033522
27485707	340	348	patients	T101	C0030705
27485707	363	380	prostate rebiopsy	T060	C0194804
27485707	409	425	negative results	T033	C1334932
27485707	433	451	rectal examination	T060	C0199900
27485707	458	462	lack	T080	C0332268
27485707	466	479	preneoplastic	T191	C0282313
27485707	480	487	lesions	T033	C0221198
27485707	493	501	patients	T101	C0030705
27485707	523	528	IGF-1	T116,T123	C0021665
27485707	529	535	levels	T080	C0441889
27485707	536	544	measured	T080	C0444706
27485707	566	591	impedance audiometry test	T060	C0001161
27485707	602	611	abdominal	T029	C0000726
27485707	612	645	Fat Analyser AB-140 TANITA system	T074	C0025080
27485707	650	660	calculated	T052	C1441506
27485707	665	711	receiver operating characteristic (ROC) curves	T081	C0035787
27485707	720	730	PSA levels	T034	C0428540
27485707	734	737	PSA	T116,T126,T129	C0138741
27485707	739	757	internal organ fat	T201	C0344335
27485707	762	767	IGF-1	T116,T123	C0021665
27485707	772	775	PSA	T116,T126,T129	C0138741
27485707	776	783	density	T081	C0178587
27485707	797	805	patients	T101	C0030705
27485707	811	820	diagnosed	T033	C0011900
27485707	826	841	prostate cancer	T191	C0600139
27485707	849	857	patients	T101	C0030705
27485707	862	882	significantly higher	T081	C4055637
27485707	883	886	PSA	T116,T126,T129	C0138741
27485707	888	892	PSAd	T116,T126,T129	C0138741
27485707	897	902	IGF-1	T116,T123	C0021665
27485707	903	909	values	T080	C0042295
27485707	933	939	higher	T080	C0205250
27485707	940	958	internal organ fat	T201	C0344335
27485707	959	965	levels	T080	C0441889
27485707	970	975	lower	T082	C0441994
27485707	978	981	PSA	T116,T126,T129	C0138741
27485707	982	990	readings	T077	C1705179
27485707	1053	1062	ROC curve	T081	C0035787
27485707	1073	1077	area	T082	C0205146
27485707	1088	1093	curve	T081	C0035787
27485707	1098	1103	IGF-1	T116,T123	C0021665
27485707	1108	1111	PSA	T116,T126,T129	C0138741
27485707	1152	1158	cutoff	T169	C1442160
27485707	1159	1165	points	T081	C1552961
27485707	1174	1185	sensitivity	T081	C0036667
27485707	1202	1210	criteria	T078	C0243161
27485707	1217	1230	indication of	T078	C0392360
27485707	1231	1239	rebiopsy	T060	C0005558
27485707	1252	1260	biopsies	T060	C0005558
27485707	1293	1304	undiagnosed	T033	C1408353
27485707	1312	1319	patient	T101	C0030705
27485707	1325	1335	clinically	T080	C0205210
27485707	1336	1347	significant	T078	C0750502
27485707	1348	1354	cancer	T191	C0006826
27485707	1357	1370	Gleason score	T033	C3203027
27485707	1386	1394	positive	T081	C1514243
27485707	1399	1425	negative predictive values	T081	C1513918
27485707	1434	1437	set	T077	C1705195
27485707	1441	1450	variables	T081	C1705098
27485707	1456	1467	higher than	T081	C0439093
27485707	1515	1519	cost	T081	C0010186
27485707	1528	1542	determinations	T059	C1148554
27485707	1550	1555	euros	T081	C1533125
27485707	1561	1568	results	T169	C1274040
27485707	1582	1591	measuring	T080	C0444706
27485707	1592	1597	IGF-1	T116,T123	C0021665
27485707	1604	1626	significantly decrease	T081	C4055638
27485707	1631	1637	number	T081	C0449788
27485707	1641	1652	unnecessary	T058	C0376708
27485707	1653	1663	rebiopsies	T060	C0005558